Notes to the Condensed Consolidated Interim Financial Statements of the Bayer Group

Key Data by Segment

Key Data by Segment

 

 

Pharmaceuticals

 

Consumer Health

 

Crop Science

 

Animal Health

 

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

3,889

4,263

 

1,520

1,601

 

2,936

3,120

 

408

440

Change1

 

+9.2%

+9.6%

 

−2.3%

+5.3%

 

−2.3%

+6.3%

 

+5.7%

+7.8%

Currency-adjusted change1

 

+12.2%

+7.4%

 

+2.2%

+2.6%

 

+1.3%

+3.2%

 

+8.8%

+4.7%

Intersegment sales

 

7

10

 

1

5

 

9

8

 

1

1

Net sales (total)

 

3,896

4,273

 

1,521

1,606

 

2,945

3,128

 

409

441

EBIT1

 

698

1,219

 

243

278

 

955

970

 

114

126

EBIT before special items1

 

929

1,255

 

275

287

 

958

1,007

 

115

126

EBITDA before special items1

 

1,261

1,502

 

383

392

 

1,089

1,115

 

122

135

Net cash provided by operating activities

 

734

973

 

197

265

 

(666)

(679)

 

(20)

(31)

Depreciation, amortization, impairment losses / loss reversals

 

563

280

 

121

106

 

131

121

 

7

9

Number of employees (as of March 31)2

 

40,315

37,840

 

13,297

12,040

 

23,224

21,256

 

3,853

3,598

Continuation of the previous table

 

 

Reconciliation

 

 

 

 

 

 

 

 

 

All Other Segments

 

Corporate Functions and Consolidation

 

Life Sciences

 

Covestro

 

Group

 

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

Q1 2016

Q1 2017

 

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

 

€ million

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Full-time equivalents

Net sales (external)

 

250

252

 

1

4

 

9,004

9,680

 

2,850

3,564

 

11,854

13,244

Change1

 

−6.7%

+0.8%

 

 

+2.6%

+7.5%

 

−5.4%

+25.1%

 

+0.5%

+11.7%

Currency-adjusted change1

 

−6.3%

+2.0%

 

 

+6.0%

+5.0%

 

−4.7%

+23.6%

 

+3.3%

+9.4%

Intersegment sales

 

425

710

 

(464)

(756)

 

 

21

22

 

Net sales (total)

 

675

962

 

(463)

(752)

 

 

2,871

3,586

 

11,854

13,244

EBIT1

 

3

(26)

 

(29)

(140)

 

1,984

2,427

 

336

689

 

2,320

3,116

EBIT before special items1

 

6

(8)

 

(27)

(138)

 

2,256

2,529

 

336

672

 

2,592

3,201

EBITDA before special items1

 

53

45

 

(25)

(135)

 

2,883

3,054

 

504

839

 

3,387

3,893

Net cash provided by operating activities

 

(3)

(167)

 

141

190

 

383

551

 

169

275

 

552

826

Depreciation, amortization, impairment losses / loss reversals

 

47

53

 

2

3

 

871

572

 

168

158

 

1,039

730

Number of employees (as of March 31)2

 

19,067

24,535

 

729

590

 

100,485

99,859

 

15,740

15,719

 

116,225

115,578